Mitochondria, often referred to as the "powerhouses" of the cell, are central to a wide array of vital biological processes, most notably cellular respiration, which generates the majority of the cell's energy in the form of ATP. Given their critical role in energy production, mitochondrial dysfunction can have widespread and serious consequences for cellular health. This dysfunction is linked to many diseases, including neurodegenerative disorders, metabolic conditions, autoimmune and cardiovascular diseases.
Mitotech's focus on protecting mitochondria from oxidative stress and enhancing energy expenditure is particularly relevant. Oxidative stress occurs when there is an imbalance between the production of reactive oxygen species (ROS) and the cell's ability to detoxify these harmful compounds. This imbalance can lead to mitochondrial damage, membrane dysfunction, and activation of cell death pathways, exacerbating the progression of many diseases, such as rare mitochondrial or metabolic disorders. Mitochondrial damage impairs cell’s ability to burn lipids for energy, which, in turn, introduces more mitochondrial damage.
By developing small molecules aimed at mitigating these processes, Mitotech is working in an exciting and essential area of drug development. These orally bioavailable molecules could potentially restore mitochondrial function and enhance energy expenditure, offering new therapeutic options for a range of diseases.